{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:54:23Z","timestamp":1790409263225,"version":"4.1.0"},"reference-count":36,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2023,1,20]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>In the phase II ELOQUENT-3 trial (ClinicalTrials.gov identifier: NCT02654132 ), elotuzumab combined with pomalidomide\/dexamethasone (EPd) significantly improved progression-free survival (PFS) versus pomalidomide\/dexamethasone (Pd) in patients with relapsed\/refractory multiple myeloma (RRMM) previously treated with lenalidomide and a proteasome inhibitor (PI). Here, we present the final overall survival (OS) results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Patients with RRMM who had received \u2265 2 prior lines of therapy, with disease refractory to last therapy and either refractory or relapsed and refractory to lenalidomide and a PI were randomly assigned (1:1) to receive EPd or Pd. The primary end point was PFS per investigator assessment. ORR and OS were secondary end points planned to be tested hierarchically.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>A total of 117 patients were randomly assigned to EPd (n = 60) and Pd (n = 57). Among treated patients (EPd 60, Pd 55), there were 37 (61.7%) deaths in the EPd group and 41 (74.5%) in the Pd group, most commonly because of disease progression (EPd 41.7%, Pd 49.1%). Median (95% CI) OS was significantly improved with EPd (29.8 [22.9 to 45.7] months) versus Pd (17.4 [13.8 to 27.7] months), with a hazard ratio of 0.59 (95% CI, 0.37 to 0.93; P = .0217). OS benefit with EPd was observed in most patient subgroups. The safety profile of EPd was consistent with prior reports with no new safety signals detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>EPd demonstrated a statistically significant improvement in OS versus Pd in patients with RRMM previously treated with lenalidomide and a PI who had disease refractory to last therapy. In this setting, ELOQUENT-3 is the first randomized study of a triplet regimen incorporating a monoclonal antibody and Pd to improve both PFS and OS significantly.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.21.02815","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T15:59:27Z","timestamp":1660319967000},"page":"568-578","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":109,"title":["Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed\/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial"],"prefix":"10.1200","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct02654132","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"first","affiliation":[{"name":"National and Kapodistrian University of Athens School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0855-6591","authenticated-orcid":false,"given":"Dominik","family":"Dytfeld","sequence":"additional","affiliation":[{"name":"Karol Marcinkowski University of Medical Sciences, Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Grosicki","sequence":"additional","affiliation":[{"name":"Silesian Medical University, Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-8746","authenticated-orcid":false,"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"University Hospital, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Takezako","sequence":"additional","affiliation":[{"name":"National Hospital Organization Disaster Medical Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1762-3592","authenticated-orcid":false,"given":"Mitsuo","family":"Hori","sequence":"additional","affiliation":[{"name":"Ibaraki Prefectural Central Hospital, Kasama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-4170","authenticated-orcid":false,"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Poitiers\u2013La Mil\u00e9trie, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"H\u00f4pital Maisonneuve-Rosemont, University of Montreal, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Japanese Red Cross Medical Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4181-6922","authenticated-orcid":false,"given":"Marc S.","family":"Raab","sequence":"additional","affiliation":[{"name":"Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-8865","authenticated-orcid":false,"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Dana\u2013Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Popa McKiver","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ming","family":"Jou","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Yao","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prianka","family":"Das","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jes\u00fas","family":"San-Miguel","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Universidad de Navarra (CCUN), Centro de Investigaci\u00f3n M\u00e9dica Aplicada, Instituto de Investigaci\u00f3n Sanitaria de Navarra (IDISNA), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","volume-title":"SEER Cancer Statistics Review, 1975-2018","author":"Howlader N","year":"2021"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.307"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.138"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4246"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-107292"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1610-3"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1493-8"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1339853"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0998"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147323"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30354-9"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00103-X"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-360552"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00357-4"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.66"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.119"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.238"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-611426"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805762"},{"key":"b22","volume-title":"Empliciti Summary of Product Characteristics","author":"European Medicines Agency","year":"2019"},{"key":"b23","volume-title":"Empliciti\u00ae (Elotuzumab) Product Information (Switzerland)","author":"Bristol Myers Squibb SA","year":"2019"},{"key":"b24","volume-title":"New Drugs Approved in FY 2019","author":"Japan Pharmaceuticals and Medical Devices Agency","year":"2019"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000563756.72895.a3"},{"key":"b27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30452-6"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785246"},{"key":"b29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00128-5"},{"key":"b30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8017"},{"key":"b31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.623"},{"key":"b32","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0711-6"},{"key":"b33","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00359-2"},{"key":"b34","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017006866"},{"key":"b35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3117"},{"key":"b36","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1688324"},{"key":"b37","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"b38","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.21.02815","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T18:02:28Z","timestamp":1673978548000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.21.02815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,1,20]]}},"alternative-id":["10.1200\/JCO.21.02815"],"URL":"https:\/\/doi.org\/10.1200\/jco.21.02815","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]},"assertion":[{"value":"2021-12-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}